Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic Cancer Center at Sacred Heart
mi
from
Eau Claire, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sacred Heart Hospital
mi
from
Eau Claire, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sacred Heart Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Health Center-Fond du Lac
mi
from
Fond Du Lac, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Health Center-Fond du Lac
mi
from
Fond Du Lac, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Grafton
mi
from
Grafton, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Grafton
mi
from
Grafton, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology at Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology Limited at Saint Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora BayCare Medical Center
mi
from
Green Bay, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora BayCare Medical Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Health System
mi
from
Janesville, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Health System
mi
from
Janesville, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Kenosha South
mi
from
Kenosha, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Kenosha South
mi
from
Kenosha, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Bay Area Medical Center
mi
from
Marinette, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Vince Lombardi Cancer Clinic - Marinette
mi
from
Marinette, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Vince Lombardi Cancer Clinic - Marinette
mi
from
Marinette, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic
mi
from
Marshfield, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Joseph's Hospital
mi
from
Marshfield, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Joseph's Hospital
mi
from
Marshfield, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Milwaukee
mi
from
Milwaukee, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Saint Lukes Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Sinai Medical Center
mi
from
Milwaukee, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Sinai Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic Minocqua Center
mi
from
Minocqua, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Vince Lombardi Cancer Clinic - Oshkosh
mi
from
Oshkosh, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Vince Lombardi Cancer Clinic - Oshkosh
mi
from
Oshkosh, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Racine
mi
from
Racine, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Racine
mi
from
Racine, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic at James Beck Cancer Center
mi
from
Rhinelander, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic at James Beck Cancer Center
mi
from
Rhinelander, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Mary's Hospital
mi
from
Rhinelander, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Mary's Hospital
mi
from
Rhinelander, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic Rice Lake Center
mi
from
Rice Lake, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Vince Lombardi Cancer Clinic - Sheboygan
mi
from
Sheboygan, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Vince Lombardi Cancer Clinic - Sheboygan
mi
from
Sheboygan, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic Cancer Care at Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Michael's Hospital
mi
from
Stevens Point, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Green Bay Oncology - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Medical Center in Summit
mi
from
Summit, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Medical Center in Summit
mi
from
Summit, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Waukesha
mi
from
Waukesha, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Waukesha
mi
from
Waukesha, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic - Wausau Center
mi
from
Wausau, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora Cancer Care-Milwaukee West
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Aurora West Allis Medical Center
mi
from
West Allis, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Aurora West Allis Medical Center
mi
from
West Allis, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic - Weston Center
mi
from
Weston, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic - Weston Center
mi
from
Weston, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Clare's Hospital
mi
from
Weston, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Clare's Hospital
mi
from
Weston, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Marshfield Clinic - Wisconsin Rapids Center
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Rocky Mountain Oncology
mi
from
Casper, WY
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Rocky Mountain Oncology
mi
from
Casper, WY
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Big Horn Basin Cancer Center
mi
from
Cody, WY
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Big Horn Basin Cancer Center
mi
from
Cody, WY
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Billings Clinic-Cody
mi
from
Cody, WY
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Billings Clinic-Cody
mi
from
Cody, WY
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Welch Cancer Center
mi
from
Sheridan, WY
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Welch Cancer Center
mi
from
Sheridan, WY
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Community Cancer Center Foundation
mi
from
Normal, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Community Cancer Center Foundation
mi
from
Normal, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Lankenau Medical Center
mi
from
Wynnewood, PA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Lankenau Medical Center
mi
from
Wynnewood, PA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
The University of Arizona Cancer Center - North Campus
mi
from
Tucson, AZ
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
The University of Arizona Cancer Center - North Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente - Anaheim
mi
from
Anaheim, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente - Anaheim
mi
from
Anaheim, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-Baldwin Park
mi
from
Baldwin Park, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-Baldwin Park
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Kaiser Permanente-Bellflower
mi
from
Bellflower, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Kaiser Permanente-Bellflower
mi
from
Bellflower, CA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials